Differences between treatments were deemed to be extremely significant, very significant, significant and not significant if their p values (according to Bonferroni's comparison test) were <0.001, <0.01, 0.01 < p < 0.05 and >0.05, respectively.
← all excerpts
PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
1
—
—